Company of the week: Suzhou Ribo Life Science
Company of the week: Suzhou Ribo Life Science
Company Overview and Technology
Suzhou Ribo Life Science (Ribo, HKEX: 06938) is
Fund of the week: Flagship Pioneering
Overview and Investment Focus
Flagship Pioneering is not a venture capital firm in the traditional sense — it is a venture
The Warrant Sweetener: How Equity Kickers Are Reshaping Pharmaceutical Royalty Deals
When ADC Therapeutics filed an 8-K on February 23, 2026, the headline was the dramatic reduction of its change-of-control payment
Transfer Pricing and Intercompany Royalties in Pharma: How BEPS Is Rewriting the Rules of Royalty Financing
When the IRS informed Amgen in 2021 that it owed $10.7 billion in back taxes and penalties—the largest
Royalty Financing for Biosimilars: Structure, Economics, and Modelling Considerations
Biosimilar companies are capital-intensive, margin-constrained, and acutely exposed to competitive timing risk. They spend $100 million to $250 million developing
The Weekly Term Sheet (2026-W08)
The week of February 15–21, 2026 recorded approximately $16.5 billion in aggregate announced transaction value across 35+ discrete events.
Syndication in Biopharma Royalty Financings: Why $900 Million Deals Still Don't Have a Syndicate
When Agios Pharmaceuticals sold its vorasidenib royalty to Royalty Pharma for $905m in 2024, a single buyer wrote the entire
Company of the week: Iambic Therapeutics
Iambic Therapeutics is a San Diego-based clinical-stage biotechnology company using physics-informed artificial intelligence to discover and develop novel small-molecule drugs, primarily in oncology.
Fund of the week: NKF Innovation Fund
How the National Kidney Foundation is betting venture philanthropy can transform kidney care — and what could go wrong.
Step-In Rights in Pharmaceutical Licensing and Royalty Transactions
Step-in rights are contractual provisions allowing one party to assume operational control when the counterparty fails to perform. In pharmaceutical
